Recursion raises $200M in oversubscribed offering, extends runway to 2029
What's the deal? Recursion, a Salt Lake City clinical-stage drug discovery company, raised $200 million in an oversubscribed follow-on stock offering. Janus Henderson Investors, InvusDealroom has a profile for this one. Try Dealroom →, Longaeva PartnersDealroom has a profile for this one. Try Dealroom →, ARK InvestDealroom has a profile for this one. Try Dealroom →, and Driehaus Capital ManagementDealroom has a profile for this one. Try Dealroom → joined the round, which was announced October 15, 2026.
What's the endgame? Recursion uses AI to decode biology and develop medicines. The company said the proceeds extend its cash runway into 2029, funding its highest-conviction programs and upcoming clinical milestones.
Why now? The raise coincides with fresh pipeline data. Its lead candidate REC-4881, targeting Familial Adenomatous Polyposis (FAP), showed a 47% median reduction in polyp burden after 12 weeks, plus new upper GI data with a 55% median reduction — addressing what the company calls the area of greatest unmet need.
Recursion pegs the FAP opportunity at $15 billion, citing more than 50,000 patients across the US and EU5 with no approved therapies. It is targeting a registrational trial in the second half of 2027, pending FDA discussions.
What else? Recursion reported early Phase 1 results for its cancer candidate REC-1245, including two confirmed partial responses in endometrial cancer and a 91.7% disease control rate at higher doses. Separately, partner Sanofi optioned a potential first-in-class immunology candidate from their collaboration.
Chief executive officer Najat Khan said the financing strengthens the company's ability to "advance our highest-conviction programs, deliver on upcoming clinical milestones, and build long-term value with focus and discipline."
The signal: At $200 million, the raise ranks in the 90th percentile of all US post-IPO equity rounds in healthcare, underscoring investor appetite for AI-driven drug discovery backed by clinical proof points rather than platform promises alone.
Read more: benzinga.com
Image credit: Generated with Gemini
